Metformina Doc

Metformin Hydrochloride, the active ingredient in Metformina Doc, is a Biguanide presented as an unknown strength/unknown form for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to control elevated blood glucose levels.

GNH USA supplies Metformina Doc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards, is manufactured under strict Good Manufacturing Practices, and is distributed through regulated channels to ensure product integrity and patient safety.

Metformina Doc (metformin hydrochloride) is used in the treatment of disorders related to glucose metabolism, primarily type 2 diabetes.

- Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial glucose levels. - Prediabetes (impaired glucose tolerance): delays progression to overt type 2 diabetes. - Polycystic ovary syndrome: enhances insulin sensitivity and may help restore ovulatory function.

Metformina Doc may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: transient gastrointestinal upset that often resolves with continued therapy. - Diarrhea: loose stools that may be mitigated by dose titration. - Abdominal discomfort: cramping or bloating, usually mild. - Metallic taste: temporary alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening accumulation of lactate, especially in patients with renal impairment. - Severe allergic reaction: including skin rash, Stevens‑Johnson syndrome, or anaphylaxis. - Hepatotoxicity: marked elevation of liver enzymes indicating liver injury.

Before initiating Metformina Doc, clinicians should evaluate patient‑specific risk factors and monitor therapy appropriately. - Renal function: assess creatinine clearance and avoid use in severe renal impairment. - Lactic acidosis risk: contraindicated in patients with significant hepatic disease or conditions predisposing to hypoxia. - Alcohol consumption: limit intake as it may increase the risk of lactic acidosis. - Surgery or radiologic contrast studies: consider temporary discontinuation to protect renal function. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Metformina Doc can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate renal dysfunction and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations, heightening toxicity. - Alcohol: synergistic effect on lactic acidosis development.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycemia. - Diuretics (loop or thiazide): can affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and electrolytes during combined therapy.